Search results
Showing 136 to 150 of 1242 results for public health guidance
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]
In development Reference number: GID-TA11995 Expected publication date: 08 October 2026
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
In development Reference number: GID-TA11643 Expected publication date: 17 September 2026
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]
In development Reference number: GID-TA11742 Expected publication date: 29 July 2026
In development Reference number: GID-TA11802 Expected publication date: TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 17 September 2026
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 17 September 2026
Deferred Reference number: GID-TA11531
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]
In development Reference number: GID-HST10069 Expected publication date: TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
In development Reference number: GID-TA11886 Expected publication date: 13 May 2027
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)
This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026